Alejandro Galindo - May 10, 2022 Form 4 Insider Report for MANNKIND CORP (MNKD)

Role
EVP Endocrine Business Unit
Signature
/s/ Alejandro Galindo
Stock symbol
MNKD
Transactions as of
May 10, 2022
Transactions value $
$0
Form type
4
Date filed
5/12/2022, 08:01 PM
Previous filing
Mar 1, 2022
Next filing
May 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNKD Restricted Stock Unit Award $0 +90K +15.61% $0.00 667K May 10, 2022 Direct F1, F2
transaction MNKD Restricted Stock Unit Award $0 +110K +16.5% $0.00 777K May 10, 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
F2 Acquired pursuant to a Restricted Stock Unit Award: 25% vest on each year annivesary of the vesting determination date and 25% each anniversary thereafter; shares shall fully vest on the fourth year anniversary of the vesting determination date.
F3 The restricted stock unit will vest on May 10, 2025 provided that the closing price of MannKind common stock on such vesting date is not less than the closing price on May 10, 2022. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from May 10, 2022 until May 10, 2025 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.